Login to Your Account



Acambis Follows ACAM 2000 Trouble With West Nile Glitch

By Nuala Moran


Wednesday, June 2, 2004
LONDON - Acambis plc was forced to double the number of subjects in a Phase I study of its West Nile vaccine after two adverse events forced suspension of the trial. The expansion, from 60 to 120 subjects, will delay the results until 2005. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription